Generic Name: elvitegravir + cobicistat + tenofovir alafenamide + emtricitabine
Drug Class: Single-Tablet Regimens
Company: Gilead Sciences
Approval Status: Approved
Generic Version Available: No
The U.S. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents lists Genvoya as a recommended initial HIV treatment regimens in certain clinical situations. Visit https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0 for the full DHHS guidelines.
Genvoya is a single-tablet regimen for HIV. It contains three different types of HIV drugs: two nucleotide/nucleoside reverse transcriptase inhibitors and one integrase inhibitor. It also contains a pharmacokinetic enhancer, a drug that has no activity against HIV, but boosts the blood levels and effectiveness of other drugs. Genvoya was approved by the U.S. Food and Drug Administration in November 2015, for use by people living with HIV who are 12 years of age or older and who are either starting HIV treatment for the first time or those wishing to switch their current regimens (provided that they have been on a stable regimen for at least six months, have an undetectable viral load and no history of HIV treatment failure or resistance to any of the drugs in Genvoya).
Genvoya is a combination of four drugs: Vitekta (elvitegravir), tenofovir alafenamide, Emtriva (emtricitabine) and Tybost (cobicistat). Vitekta, Emtriva and Tybost can be purchased individually for use in combination with other HIV drugs. Tenofovir alafenamide is currently unavailable as a standalone drug.
Adult Dose: One tablet once a day. Each tablet contains 150 mg elvitegravir, 150 mg cobicistat, 10 mg tenofovir alafenamide fumarate and 200 mg emtricitabine.
Pediatric Dose: N/A
Dosing Info: This is a complete one-pill, once-daily drug regimen. Take with food.
Common side effects include gastrointestinal symptoms, notably diarrhea and nausea, fatigue, and headache.
Genvoya may lead to new or worsening kidney problems, though this risk is lower compared with those using Stribild. Your healthcare provider may do blood tests to check your kidneys before and during treatment with Genvoya.
Genvoya may lead to bone problems, though this risk is lower compared with those using Stribild. Problems include bone pain or bones getting soft or thin, which may lead to fractures. Your healthcare provider may do tests to check your bones.
If you also have hepatitis B virus (HBV) and take Genvoya, your hepatitis may become worse if you stop taking Genvoya. Do not stop taking Genvoya without first talking to your healthcare provider.
For a review of drug interactions, including prescription and over-the-counter medications and supplements that should not be taken with Genvoya or may require dose adjustments, consult the Genvoya package insert: http://www.gilead.com/~/media/files/pdfs/medicines/hiv/genvoya/genvoya_pi.pdf?la=en
Before taking this medication, tell your doctor if you have kidney disease or liver disease (including hepatitis B). In addition, tell your doctor if you are pregnant or planning to become pregnant; if you are breast feeding, and all your medical conditions, including all prescription and over-the-counter medications and supplements you are taking.
Co-Pay Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs
Patient Assistance Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs
Last Reviewed: May 21, 2019